University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Biochemistry -- Faculty Publications

Biochemistry, Department of

2010

Identification and characterization of small
compound inhibitors of human FATP2
Angel Sandoval
University of Nebraska-Lincoln

Aalap Chokshi
Albany Medical College

Elliot D. Jesch
University of Nebraska-Lincoln

Paul N. Black
University of Nebraska-Lincoln, pblack2@unl.edu

Concetta C. DiRusso
University of Nebraska-Lincoln, cdirusso2@unl.edu

Follow this and additional works at: http://digitalcommons.unl.edu/biochemfacpub
Part of the Biochemistry Commons, Biotechnology Commons, and the Other Biochemistry,
Biophysics, and Structural Biology Commons
Sandoval, Angel; Chokshi, Aalap; Jesch, Elliot D.; Black, Paul N.; and DiRusso, Concetta C., "Identification and characterization of
small compound inhibitors of human FATP2" (2010). Biochemistry -- Faculty Publications. 204.
http://digitalcommons.unl.edu/biochemfacpub/204

This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It
has been accepted for inclusion in Biochemistry -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska Lincoln.

NIH Public Access

PMCID: PMC2814954

Author Manuscript
Biochem Pharmacol. Author manuscript; available in PMC 2011 April 1.

NIH-PA Author Manuscript

Published in final edited form as:
Biochem Pharmacol. 2010 April 1; 79(7): 990. doi:10.1016/j.bcp.2009.11.008.
Copyright © 2009 Elsevier Inc.

Identification and characterization of small compound inhibitors
of human FATP2
Angel Sandovala, Aalap Chokshib, Elliot D. Jescha, Paul N. Blacka, and Concetta C.
DiRussoa,c,*
a Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0664
b

Center for Cardiovascular Sciences, Albany Medical College, Albany, NY 12208

c

Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE
68583-0806

Abstract
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Fatty acid transport proteins (FATPs) are bifunctional proteins, which transport long chain fatty acids
into cells and activate very long chain fatty acids by esterification with coenzyme A. In an effort to
understand the linkage between cellular fatty acid transport and the pathology associated with
excessive accumulation of exogenous fatty acids, we targeted FATP-mediated fatty acid transport
in a high throughput screen of more than 100,000 small diverse chemical compounds in yeast
expressing human FATP2 (hsFATP2). Compounds were selected for their ability to depress the
transport of the fluorescent long chain fatty acid analogue, C1-BODIPY-C12. Among 234 hits
identified in the primary screen, 5 compounds, each representative of a structural class, were further
characterized in the human Caco-2 and HepG2 cell lines, each of which normally expresses FATP2,
and in 3T3-L1 adipocytes, which do not. These compounds were effective in inhibiting uptake with
IC50s in the low micromolar range in both Caco-2 and HepG2 cells. Inhibition of transport was highly
specific for fatty acids and there were no effects of these compounds on cell viability, trans-epithelial
electrical resistance, glucose transport, or long chain acyl-CoA synthetase activity. The compounds
were less effective when tested in 3T3-L1 adipocytes suggesting selectivity of inhibition. These
results suggest fatty acid transport can be inhibited in a FATP-specific manner without causing
cellular toxicity.
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1. Introduction
It is becoming increasingly apparent that typical western diets high in fat lead to a plethora of
pathophysiological states ranging from obesity and type 2 diabetes to coronary heart disease.
One of the hallmarks of these disease states is the accumulation of neutral lipids in the form
of triglycerides in non-adipose tissues that normally do not store significant levels of these
compounds [1,2]. In these tissues, inflammation and the generation of reactive oxygen species,
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which accompany the increased accumulation of neutral lipids, further contribute to these
pathological states. Our laboratory has been investigating the biochemical mechanisms that
govern the transport of exogenous fatty acids into cells. While this process includes a
diffusional component [3], one mechanism that we have defined is the concomitant transport
and esterification of fatty acids by a process referred to as vectorial acylation [4]. This process,
while not completely understood in higher eukaryotic systems, is thought to require a fatty acid
transport protein (FATP), which functions alone or in conjunction with a long chain acyl-CoA
synthetase (Acsl). In a yeast model, compelling evidence has been obtained showing that FATP
and Acsl (in yeast Fat1p and Faa1p or Faa4p, respectively) functionally interact at the plasma
membrane promoting vectorial acylation [5–7]. When the Fat1p structural gene (FAT1) is
deleted, the cells are unable to transport long chain fatty acids and, moreover, are unable to
convert exogenous long chain fatty acids to acyl-CoAs, despite having wild type levels of long
chain acyl-CoA synthetase activity [6,7]. In yeast cells lacking the two major Acsl structural
genes (FAA1 and FAA4), the phenotype is similar, resulting in both the elimination fatty acid
transport and the formation of long chain acyl-CoA in response to exogenous challenge [6].
The difference between the fat1Δ and faa1Δ faa4Δ strains is that in the latter there is a 96%
reduction in total acyl-CoA synthetase activity.

NIH-PA Author Manuscript

We have exploited the yeast model system to investigate the biochemical mechanisms
underlying the vectorial acylation of exogenous fatty acids. Of particular note has been the use
of a fat1Δ strain as a host in which to reconstitute the six different mammalian isoforms of
FATP [5]. These studies demonstrated that FATP1, FATP2 and FATP4 were fully functional
in fatty acid transport, while FATP3, FATP5 and FATP6 were not. We subsequently surveyed
the expression of the different FATP isoforms in a number of different mammalian cell types
and measured fatty acid transport using the fluorescent long chain fatty acid 4,4-difluoro-5methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C1-BODIPY-C12) [8]. The results
of these studies were consistent with the findings from yeast in that cells expressing FATP1,
FATP2 or FATP4 were also fatty acid transport proficient.

NIH-PA Author Manuscript

Using a yeast strain deficient in transport (fat1Δ) with depressed acyl-CoA synthetase activity
(faa1Δ) and expressing transport proficient human FATP isoforms, we developed high
throughput screening strategies to select for small molecule inhibitors of fatty acid transport
using C1-BODIPY-C12 [9,10]. The impetus behind these studies was to identify small molecule
inhibitors of fatty acid transport proceeding through a specific FATP isoform so that we could
[1] develop additional tools to understand the biochemical mechanisms that govern fatty acid
transport into cells, and [2] identify novel compounds of therapeutic value to treat pathological
states resulting from, or exacerbated by, fatty acid internalization in non-adipose tissue. In the
present study we screened two diverse compound libraries using high throughput strategies
developed in our lab; the target in these studies was human FATP2 (hsFATP2) expressed in
the yeast fat1Δ faa1Δ strain. The primary screen of just over 100,000 compounds identified
234 potential hits. On the basis of structural similarities, most could be grouped into five
different classes. All 234 compounds were subjected to secondary screens using human Caco-2
cells, which normally express hsFATP2 [8]. A selected subset, representative of the five
structural classes, were further characterized in HepG2 cells and 3T3-L1 adipocytes to test
inhibition of transport and in Caco2 cells to evaluate impact on additional parameters including
barrier function and transport of glucose.

2. Materials and methods
2.1. Materials
Yeast extract, yeast peptone, yeast nitrogen base without amino acids, and dextrose were
obtained from Difco (Detroit, MI). Complete amino acid supplement and individual amino
acids were from Sigma (St. Louis, MO). Fatty-acid-free bovine serum albumin (FAF BSA)
Biochem Pharmacol. Author manuscript; available in PMC 2011 April 1.
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and other chemical reagents were also from Sigma. The fluorescent long-chain fatty acid
analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C1BODIPY-C12) and the fluorescent glucose analog, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino)-2-deoxyglucose (2-NBDG) were purchased from Molecular Probes/Invitrogen
(Eugene, OR, USA). Radioactive fatty acid ([3H] oleate; specific activity, 5 mCi/ml) was
obtained from Perkin Elmer (Waltham, MA). BD Biosciences black with clear bottom 384well and 96-well microplates were used for primary and secondary screenings in yeast. For
Caco-2 and HepG2 cells, tissue culture treated 96-well black with clear flat bottom polystyrene
collagen coated microplates were obtained from Fisher Scientific (Pittsburgh, PA).
Transwell® Permeable Supports used for experiments involving Caco-2 cells were from
Corning Life Sciences (Acton, MA).
2.2. Cell culture and reagents

NIH-PA Author Manuscript

S. cerevisiae strain LS2086 containing deletions within the FAT1 and FAA1 genes
(fat1Δfaa1Δ; MATa ura3 52 his3200 ade2-101 lys2-801 leu2-3,112 faa1Δ::HIS3
fat1Δ::G418) expressing hsFATP2 was used for the primary high throughput screening as
detailed previously [9,11]. For most experiments, yeast minimal medium with dextrose
(YNBD) containing 0.67% yeast nitrogen base (YNB), 2% dextrose, adenine (20 mg/L), uracil
(20 mg/L), and amino acids as required [arginine, tryptophan, methionine, histidine, and
tyrosine (20 mg/L); lysine (30 mg/L); and leucine (100 mg/L)] was used. When a rich medium
was required, yeast complete media with adenine (YPDA) was used. Growth in liquid culture
and on plates was at 30 °C.
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The Caco-2 cell line is derived from a human adenocarcinoma and is able to undergo
differentiation into polarized epithelial cells that show a brush border phenotype and form welldeveloped and functional tight junction complexes [12,13]. This cell line is used as an in
vitro model to predict human intestinal absorption and secretion [14]. Caco-2 cells were
maintained in Earl’s minimal essential medium (MEM) with 20% FBS in a 95% air 5% CO2
atmosphere at 37° C, as described [8]. For growth and differentiation, the BD Biosciences
Intestinal Epithelium Differentiation Media Pack was used. Cells were plated in basal seeding
medium at a density of 2.5 × 105 cells/cm2 on a collagen-coated black-clear 96-well plate (BD
Biosciences). After 72 h in culture, the basal seeding medium was removed and Entero-STIM
medium was added to each well. Both media contained mito-serum extender. After another 24
h, cells were serum-starved for one hour in MEM without phenol red prior to performing the
C1-BODIPY-C12 uptake assay. HepG2 cells (ATCC, HB-8065) were obtained from the
American Type Culture Collection and were cultured according to the supplier’s protocols.
The cells were seeded in 96-well collagen coated plates at a seeding density of 2.5 × 105 cells/
cm2. 3T3-L1 fibroblasts (ATCC, CL-173) were maintained in modified DMEM and 10% BCS.
For differentiation into adipocytes, 3T3-L1 cells were treated with methylisobutylxanthine
(0.5mM), dexamethasone (1.0μM), and insulin (1.75μM) in DMEM and 10% FBS for 48 hours
as detailed by Student et al. [15]. After 48 hour incubation with differentiation medium, cells
were treated with DMEM and 10% FBS supplemented with insulin (1.75μM) for 48 hours.
Cells were subsequently maintained in DMEM and 10% FBS for an additional 3–6 days until
fully differentiated. The number of cells per well in screening trials were determined using the
FluoReporter® Blue Fluorometric DNA Quantitation Kit from Invitrogen.
2.3. Library Descriptions and High Throughput Screening
Two chemically diverse compound libraries were screened using our recently devised live-cell
HTS method [9]. The NCI Diversity Set Compound Library comprises 1990 chemical core
structures representative of a larger compound library of 140,000 compounds (obtained from
NCI’s Developmental Therapeutics Program (DTP)). The ChemBridge Corporation
compound library includes a diverse, drug-like collection of 100,000 compounds.
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For primary screening, LS2086 transformed with the hsFATP2 expression vector (pDB126)
or transformed with the empty vector (pDB121) along with the GAL4 transcription factor
fusion vector, pRS416Gal4-ER-VP16, [16] were pre-grown in YNBD without leucine and
uracil (YNBD-leu -ura) as described [9]. The cells were subsequently subcultured to A600 nm
of 0.02 in the same medium containing 10 nM β-estradiol to induce FATP2 expression, grown
to mid-log-phase (0.8–1.2 A600), harvested and then resuspended in PBS to a final density of
6 × 107 cells/ml prior to dispensing into a 384-well assay plate (22.5 μl/well; (1.35 × 106 cells)).
Wells in the first two rows of each 384-well plate received the vector control cells, and all other
wells in the plate received cells expressing hsFATP2. Compounds (2.5 μL) were then added
to a final concentration of 40 μM in PBS. After a 2 hr incubation at 30° C, 75 μL of the C1BODIPY-C12 transport mixture (resulting in final concentrations 1.25 μM C1-BODIPY-C12,
0.75 μM FAF BSA, 2.1 mM Trypan blue) were added to each well. After 30 min, the cellassociated fluorescence, reflective of fatty acid transport, was measured using a Bio-Tek
Synergy HT multidetection microplate reader (Bio-Tek Instruments, Inc. Winooski, VT) using
filter sets of 485 nm ± 20 excitation and 528 nm ± 20 emission. The Z′ factor for each plate
was calculated using cells expressing hsFATP and vector controls without compound
essentially as described [9]. A compound was considered a primary hit when the final
fluorescence value was three standard deviation units above or below the positive control
fluorescence value obtained for each plate assayed. All compounds that resulted in an increase
in cell-associated fluorescence were found to be autofluorescent and were not considered
further.
Secondary screens were performed to identify compounds that acted non-specifically as
described previously [9]. Compounds were eliminated from further consideration if [1] they
were autofluorescent, [2] were able to quench the BODIPY fluorophore, or [3] permeabilized
the cells to allow internalization and quenching of trypan blue. Compounds passing each of
these secondary screens were subsequently tested for activity primarily using Caco-2 cells as
detailed below.
2.4. Compound Evaluation in Caco-2 cells, HepG2 cells and 3T3-L1 Adipocytes

NIH-PA Author Manuscript

Caco-2 cells were plated in basal seeding medium at a density of 2.5 × 105 cells/cm2 in collagencoated 96-well plates, and differentiated as detailed above. HepG2 cells were cultured in
EMEM. Differentiated 3T3-L1 adipocytes were maintained in modified DMEM and 10% FBS.
After another 24 h, cells were serum-starved for 1 h in MEM without phenol red prior to
performing the C1-BODIPY-C12 transport assay [8,17]. In a standard reaction, serum-free
MEM was removed from the wells and 50 μL of the test compound in MEM (MEM alone for
controls) were added to each well and incubation was continued for 1 h. Then 50 μL of C1BODIPY-C12 mixture (final concentrations 5 μM C1-BODIPY-C12; 5 μM FAF BSA; 1.97 mM
trypan blue) was added to each well and the uptake was allowed to take place for 15 min. Cellassociated fluorescence was measured as detailed above. The inhibition of fatty acid uptake
activity using C1-BODIPY-C12 was assayed using different concentrations of selected
compounds ranging from 0.001 μM to 640 μM. Ligand competition curves were fit by nonlinear
least-squares regression using one-site competition and dose-response models and Prism
software (GraphPad software, Inc., San Diego, CA) in order to determine the compound
concentration that reduced C1-BODIPY-C12 fluorescence readout by 50% (IC50). Ki values
were calculated from the IC50 using the equation of Cheng and Prusoff as detailed in Li et al
[9] and KT values published by Sandoval et al [8].
To evaluate if inhibition of fatty acid uptake after compound treatment was reversible, cells
were seeded in 96-well plates and treated as described above, but after 1 h the media with
compound was removed, cells were washed twice with MEM, and fresh media containing
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serum was added. Cells were incubated 24 h at 37° C with 5% CO2 and then fatty acid uptake
was measured using the standard C1-BODIPY-C12 transport assay.
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2.5. Cytotoxicity Assay in Caco2 Cells
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was used to
determine if compounds of interest were cytotoxic to Caco-2 cells [18]. Cells were cultured
and differentiated as detailed above in collagen-coated 96-well plates. Cells were incubated at
37° C, 5% CO2 for at least one hour and up to 72 h in MEM containing the appropriate dilution
of compound. Following this incubation period, the media with compound was removed and
110 μL of MTT reagent (prepared in MEM (final concentration 0.45 mg/mL MTT)) was added.
After a 3 h incubation period, the reaction was terminated by the addition of 150 μL stop buffer
(0.01 N HCl in 10% SDS). The plates were incubated for 1 h at 37° C to facilitate solubilization
of formazan crystals; color development was read at A570.
2.6. Long chain Acyl-CoA Synthetase (Acsl) Activity in Caco-2 Cells After Compound
Treatment

NIH-PA Author Manuscript

Caco-2 cells were grown and differentiated in 60 mm collagen coated dishes (seeding density
2.5 × 105 cells/cm2). Following growth and differentiation as detailed above, cells were serum
starved for 1 h in MEM and then were treated for 1 h with selected compounds at specified
final concentrations. The media was subsequently aspirated off and cells washed once with 5
mL PBS, trypsinized using standard procedures and collected by centrifugation. The cell pellet
was resuspended in 1 mL STE lysis buffer (10 mM Tris-HCl pH 8.0; 0.1 M NaCl; 1 mM EDTA)
and sonicated on ice for 2 min using 3 sec on/off pulses. Samples were clarified by
centrifugation (15,000 × g, 15 min, 4° C), the supernatant was transferred to a new tube and
assayed for oleoyl-CoA synthetase activity (see below); protein concentrations were
determined using the Bradford assay using bovine serum albumin as a standard [19]. In parallel
experiments, untreated cells were used to prepare the cell extract for Acsl activity
measurements where the compound of interest was added directly to the reaction mixture.
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Oleoyl-CoA synthetase activity was determined using a reaction mixture containing 200 mM
Tris-HCl, pH 7.5, 2.5 mM ATP, 8 mM MgCl2, 2 mM EDTA, 20 mM NaF, 0.01% Triton X-100,
50 μM [3H]-oleic acid (C18:1) (dissolved in 10 mg/mL -cyclodextrin), and 0.5 mM coenzyme
A. Individual enzyme reactions were initiated by the addition of coenzyme A, incubated at 30°
C for 20 min, and terminated by the addition of 2.5 mL of Dole’s Reagent (isopropyl alcohol,
n-heptane, 1 M H2SO4 (40:10:1) [20]. The unesterified fatty acid was removed through organic
extraction using n-heptane. Acyl-CoA formed during the reaction remained in the aqueous
fraction and was quantified by scintillation counting. Data were expressed as nmol oleoyl CoA
formed/min/mg protein.
2.7. Assessment of the Trans Epithelial Electrical Resistance (TEER)
Caco-2 cells were seeded at 2.5 × 105 cells/cm2 in a 12-well system using Collagen-Coated
Transwell®-COL Inserts (Corning Life Sciences). For growth and differentiation, 100 μL of
relevant culture medium was added to the upper compartment and 600 μL was added to the
lower compartment of each transwell. To assess integrity of the epithelial barrier after
compound treatment, the trans epithelial electrical resistance (TEER) test was used. Confluent
and fully differentiated cells were starved of serum for 1 h in MEM without phenol red.
Subsequently, 100 μL of MEM containing the selected compound or MEM alone were added
to the upper compartment and cells were further incubated 1h at 37° C, 5% CO2. Trans epithelial
electrical resistance was then measured using the Millipore Millicell®-ERS system. For each
experiment background resistance was determined on a transwell insert without cells.
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2.8. Inhibition of Uptake of [3H]-Oleic Acid by Caco-2 cells After Compound Treatment
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To assess the inhibition of fatty acid transport using a native fatty acid ligand, 5 μM [3H]-oleate
(3.75 μmol/μCi) in 5 μM BSA was added to 60 mm culture dishes containing monolayers of
confluent Caco-2 cells differentiated as detailed above that had been pretreated with the
compound of interest for 1 h. The transport reaction was initiated by the addition of [3H]-oleate
and incubation continued for 3 min. Uptake was stopped by the addition of 6 mL of 100 μM
BSA prepared in MEM. The stop cocktail was removed by aspiration and cells rinsed once
with a solution 50 μM BSA in MEM to eliminate non-transported fatty acid. Cells were
trypsinized, scraped from the culture disk and collected by centrifugation (5 min, 1,500 × g).
The supernatant was discarded and cells were resuspended in 1 mL of MEM. Triplicate aliquots
(20 μL) of the cell suspension were used to measure cell-associated radioactivity, which is
reflective of fatty acid transport. A cell aliquot of 40 μL was used to determine the number of
viable cells using a bright-line hematocytometer in the presence of 0.4% Trypan blue (w/v).
Results were expressed as pmol of fatty acid transported/100,000 cells/3 min. Experiments
were repeated at least 3 times.
2.9. Assessment of Glucose Uptake into Caco-2 Cells
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To assess the impact of selected compounds upon glucose transport, Caco-2 cells were seeded
and differentiated in 96-well collagen coated plates as detailed above and incubated for 1 h
with compound diluted in PBS. Glucose transport was assessed by the addition of 50 μL of 2(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG; final concentration
256 μM) a fluorescent glucose analog [21]. Cells were incubated 30 min at 37° C, 5% CO2 to
allow uptake. The medium was removed by aspiration and cells rinsed once with 100 μL of
PBS. Cell-associated fluorescence was measured using a Bio-Tek Synergy HT multidetection
microplate reader using 485 ± 20 nm (excitation), 528 ± 20 nm (emission) filter set.
2.10 Data analysis
Values in arbitrary units of the fluorescent signals (AFU) from each HTS plate were acquired
using KC4 software in a BioTek Synergy plate reader. These values were exported to Excel
(Microsoft Corp., Redmond, WA, USA) spreadsheet templates and the assay quality control
Z′ factor was calculated as described [9]. ChemTree software (Golden Helix, Inc., Bozeman,
MT, USA) was used for additional statistical analysis and to study structure-activity
relationships.

3. Results
3.1. High Throughput Screening in Humanized Yeast
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Using yeast cells in which fatty acid transport was dependent upon hsFATP2, we screened two
libraries with over 100,000 chemically diverse compounds for inhibition of fatty acid transport
using the fluorescent fatty acid analogue C1-BODIPY-C12 [9,10]. Using a selection criterion
of a change in fluorescence of 3 standard deviation units from the mean of untreated control
cells, this screen identified 234 compounds as potential inhibitors of fatty acid transport. Of
these, 8 were eliminated because they quenched the fluorescent signal of C1-BODIPY-C12;
another 10 were eliminated because they apparently disrupted the membrane and increased
permeability. The remaining 216 compounds were clustered into structural classes using
ChemTree (Golden Helix) and JChem (ChemAxon) analysis software. Compounds that were
similar in structure to the atypical antipsychotics identified in a previous screening trial were
not considered further since compounds of this type may cause hypertriglyceridemia and other
metabolic disturbances upon chronic administration in patients [9]. After structural clustering,
most compounds fell into 5 structural classes and a representative of each was chosen for
extensive characterization in yeast, 3T3-L1 adipocytes, HepG2 hepatocytes and Caco-2
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intestinal epithelial cells. Table 1 lists the names and shows the structures of the selected
compounds, as well as the IC50 for transport inhibition in Caco-2 and HepG2 cells as well as
3T3-L1 adipocytes. These compounds inhibited fatty acid transport in Caco-2 and HepG2 cells
at concentrations in the low micromolar range (Table 1) and resulted in sigmoidal dose response
curves (Figure 1). These compounds were not as effective in inhibiting C1-BODIPY-C12
transport in 3T3-L1 adipocytes and resulted in higher IC50 values (Table 1,Figure 2), which
may be reflective of the different isoforms of FATP being expressed [8]. When tested in Caco-2
cells, none of the selected compounds at 10 times the IC50 dosage resulted in cellular toxicity
as measured using the MTT assay (Figure 3).
3.2 Reversibility of Selected Compound Action on Fatty Acid Transport
We evaluated whether or not inhibition of fatty acid transport was reversible by incubating
Caco-2 cells with compound for one hour, rinsing the cells with MEM and replacing the culture
media. After a 24 hour recovery period, fatty acid uptake returned to essentially the
pretreatment levels (Table 2). Further characterization was aimed at confirming specific
hsFATP mediated fatty acid transport inhibition by these different compounds.
3.3. Inhibition of Fatty acid Transport was Not Due to Nonspecific Effects on the Membrane
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We were concerned that treatment with compound might have adverse effects on membrane
barrier function by altering, for example, membrane lipid or protein composition. To test if
this might be the case, we evaluated the trans epithelial electrical resistance (TEER) in Caco2
cells treated with each of the compounds. None of the compounds caused a significant (p <
0.05) change in membrane permeability by this test (Figure 4A).
To evaluate whether other membrane specific processes were disrupted, we measured the
transport of the fluorescent glucose analogue 2-NBDG into differentiated Caco-2 cells
following incubated with the selected compounds. Glucose transport was not affected by
compounds CB-2, CB-5, CB-6 or CB-16 at 20μM, a dosage that maximally inhibits C1BODIPY-C12 transport. NCI-3 at 50μM reduced 2-NBDG transport slightly (Figure 4B).
3.4 Inhibition of the Transport of Native Fatty Acids
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The fluorescent fatty acid analogue C1-BODIPY-C12 is transported and metabolized in a
manner similar to the natural fatty acids [9,22]. However, there is always the concern the three
fused rings of the BODIPY moiety that do not occur in natural fatty acids might interact with
the fatty acid transport apparatus in a manner that is distinct from the native ligands. Therefore
we measured fatty acid transport into cells using radioactively labeled oleate ([3H]-C18:1). The
transport of [3H]-C18:1 is linear within the first 5 minutes following initiation of the experiment
(data not shown). To test inhibition by our selected fatty acid transport inhibitors, we treated
differentiated Caco-2 cells with compounds for 1 hour and measured fatty acid transport using
[3H]-C18:1 over a 3 minute period. As shown in Figure 5, the transport of oleate, a representative
native fatty acid ligand, was significantly inhibited by all 5 compounds (p ≤ 0.01). These
observations corroborate results obtained using C1-BODIPY-C12 to monitor fatty acid
transport and inhibition.
3.5. Acsl Activity Remained Unchanged Following Compound Treatment
Upon entry into a cell fatty acids are activated to CoA thioesters by acyl-CoA synthetase (Acsl)
in order to enter lipid metabolic pathways. We have shown that in yeast both FATP and Acsl
are required for fatty acid transport through the process of vectorial acylation [6,7]. As we
selected these small compound inhibitors using a live cell assay, there remained the possibility
that Acsl, as opposed to hsFATP2, was the target thereby blocking fatty acid transport. To
address whether Acsl was the target of the selected compounds, we pretreated differentiated
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Caco-2 cells with compound for 1 hour, removed the compound by rinsing, and then assayed
oleoyl CoA synthetase activity in total cell extracts. Oleoyl CoA synthetase activity was not
reduced by treatment with CB-5, CB-6, CB-16, or NC-I3 (Figure 6). CB-2, on the other hand
at 50μM (10 times the IC50), inhibited activity by about 50%. Similar results were obtained
when the compounds were added to cell extracts rather than whole cells (data not shown).
3.6. Comparison of the Activities of Structurally Related Compounds
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To test structural features important in inhibition of fatty acid transport by the selected
compounds, we next addressed fatty acid transport inhibition of related compounds available
from the ChemBridge compound database. The structures can be found in Table 3 and predicted
chemical properties in supplemental Table 1. Five compounds similar to CB-2 were evaluated
and most were 50 to 100 times less potent than the parent compound (Table 3). One compound,
CB-2.3, had an IC50 similar to CB2. The only difference between CB-2 and CB-2.3 is fluorine
on the R1 phenolic ring as opposed to chlorine. Replacing the sulfur at position R2 with oxygen
increases the IC50 by 25- to 126-fold. The positions of the methyl ether, hydroxyl and Br on
the R3 phenolic ring in CB-2 and CB-2.3 are identical and likely contribute to the ability to
block fatty acid transport with comparable efficiency. We tested three related compounds
similar to CB-5 and found that the nitrite at position R1 appears to be essential for activity
(Table 3B). Only one compound similar to CB-6, CB-6.1, was tested; it was nearly 50-fold
less effective (Table 3C). The R groups differ considerably between CB-6 and CB6.1 and thus
no conclusions can be made regarding functional groups that disrupt fatty acid transport. We
next tested two additional compounds related to CB-16 and found that both had IC50s in the
same range as CB-16 (Table 3D). The bromine at position R2 appears to be more critical for
maximal activity as opposed to the hydroxyl at position R1.

4. Discussion
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Fatty acid transport into cells occurs through a complex process that consists of both diffusional
and protein-mediated components. The protein-mediated processes, including those that
proceed though selected members of the fatty acid transport protein (FATP) family, are likely
to be operational within normal physiological concentrations of fatty acids. In the present work
we reconstituted human FATP2 in a yeast strain deficient in its native FATP, Fat1p. In this
strain, the fatty acid transport process was fully restored and dependent upon the expression
of hsFATP2. Employing this humanized yeast strain and our recently developed HTS method
of fatty acid transport using the fluorescent fatty acid analogue C1-BODIPY-C12, we screened
over 100,000 compounds from one commercial (ChemBridge, Corp.) and one public (NCI)
compound library for compounds that decreased fatty acid transport. Among the hits identified,
5 compounds, representative of distinct structural classes, were chosen for further
characterization since they inhibited transport in the low micromolar concentration ranges in
yeast and in two different human cell types that are used as models for intestinal epithelial cells
(Caco2) and hepatocytes (HepG2) that also preferentially express FATP2 [8]. The inhibitory
properties of each of these 5 compounds was reversible, none disrupted the barrier function of
Caco-2 epithelial cells, and each specifically blocked fatty acid transport without disrupting
glucose transport or perturbing cell integrity. It was of interest to find that these compounds
were less effective in blocking fatty acid transport in 3T3-L1 adipocytes, which express
FATP1. Collectively, these studies demonstrate that these five compounds represent lead
candidates as mechanistic inhibitors of fatty acid transport mediated through hsFATP2 with
potential therapeutic applications.
Previously, we demonstrated that when expressed in yeast defective in fatty acid transport
(fat1Δ), three FATP isoforms were able to substitute for the yeast FATP, Fat1p. Amongst these
was FATP2, the focus of the current study. FATP2 was chosen as the target for these studies
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since it is expressed in two human cell lines often used for drug discovery and characterization:
HepG2, a line derived from human hepatoma with many characteristics of normal hepatocytes
and Caco-2 cells derived from an adenocarcinoma with many characteristics of intestinal
epithelial cells [8]. We also addressed whether the selected compounds had the same efficacy
when tested in 3T3-L1 adipocytes, which predominantly express FATP1 [8]. FATP2 was first
identified as a very long chain acyl-CoA synthetase, called ACSVL1[23]. In fact, all of the
FATP family members share amino acid identities and domain architecture similar to the Acsvl
family [24]. Our lab demonstrated functional distinctions between long chain fatty acid
transport and very long chain activation activities by analysis of an extensive set of FAT1 alleles
mutated in one amino acid [25]. The conclusions made in analyzing these yeast mutants, that
activation and transport functions could be distinguished, were further supported by our
analysis of six murine FATPs expressed individually in a yeast fat1Δ strain. In this case,
FATP1, FATP2 and FATP4 could compliment the long chain fatty acid transport deficiency
while FATP3, 5 and 6 could not [26]. The current study now provides additional chemical
tools with which to further explore contributions of FATP proteins to fatty acid transport.
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Our initial screens in yeast provided an effective means to eliminate compounds that decreased
cell associated fluorescence through non-specific processes including quenching of the
fluorescent fatty acid analogue, permeabilization of the cell membrane, and cytotoxicity.
Cytotoxicity was also further evaluated in Caco-2 cells for each of the lead compounds. The
compounds selected as part of the final set inhibited fatty acid transport of both the fluorescently
labeled fatty acid (C1-BODIPY-C12) and radioactively labeled fatty acid at low concentrations
reflective of the physiological norm. The inhibitors were highly specific for fatty acid transport
and did not disrupt other membrane functions; glucose transport was not affected nor was the
barrier function of the Caco-2 cells.
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One process by which fatty acid transport occurs is through vectorial acylation, which involves
specific FATP isoforms that function alone or on concert with a long chain acyl-CoA synthetase
(Acsl) [11]. In this coupled transport mechanism the exogenous fatty acid is activated by
esterification with coenzyme A concomitant with transport. Fatty acid activation is also
required for all subsequent intracellular metabolic transformations. Therefore, in the absence
of a cell free binding assay for FATP-fatty acid transport activity, it was important to
demonstrate that acyl-CoA synthetase activity was not affected by compound treatment. In the
humanized yeast strain, the Acsl providing the activation function coupled to transport is Faa4p.
In Caco-2 and HepG2 cells, the specific Acsl required for activation of imported fatty acids
has not been defined. We demonstrated that the selected inhibitory compounds did not alter
total Acsl activity using two strategies. First, treatment of differentiated Caco-2 cells with the
different compounds followed by a washout, did not disrupt oleoyl-CoA synthetase activity in
cell extracts; second, Acsl activity was not inhibited when the compounds were directly added
to the cell extracts in the reaction mixture. These findings clearly point out that fatty acid
transport, likely at the level of FATP2 only, was the target for the selected compounds as long
chain acyl-CoA synthetase activity was not decreased. To this end, we conclude that these
compounds specifically inhibit fatty acid transport into the cell.
As part of our studies, we addressed whether the expression of a specific FATP isoform
changed the efficacy of the selected compounds. As noted above, Caco-2 and HepG2 cells
express FATP2 and when treated with the selected compounds gave IC50s in the low
micromolar range. When tested in 3T3-L1 adipocytes, the resultant IC50s ranged from 52 to
900 μM. These cells express FATP1 as opposed to FATP2. While there are differences in these
cell types beyond the specific FATP isoform expressed, these data indicate that these
compounds may be more selective towards FATP2 in the context of fatty acid transport.
Further, these data indicate that these compounds may allow more detailed dissection of the
individual roles provided by the different FATP isoforms.
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A limited number of structurally related compounds were also assessed for ability to inhibit
transport. For CB-2 we were able to distinguish a number of features that were essential for
activity. The substitution of oxygen for sulfur (R2, Table 3A) as in CB-2.4 and CB2.5
significantly decreased activity (25- to 100-fold). Removal of the bromine at position 3 in
CB-2.1 (R3 Table 3A) resulted in a 30-fold drop in activity. In contrast, substitution of the
chlorine for fluorine at position 3 in CB-2.3 did not affect activity. This series of compounds
and its analogs with a range of potencies in the micromolar range will serve as a reference base
from which we will be able to determine structure activity relationships.
The data set for compounds related to CB-5, CB-6 and CB-16 are relatively small and effects
on activity more modest. We did determine that the nitrite group on CB-5 (R1, Table 3B) is
important for activity as removal decreased activity about 10-fold. Only one compound was
available to us related to CB-6 in which the diazepin ring was substituted with a
dihydropyrazol-3-ylidene ring and activity was greatly reduced. Substitution or removal of the
hydroxide and bromide on CB-16 (R1 and R2, Table 3D) did not change activity.
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In the present work we have identified a group of 5 diverse compounds that decrease hsFATP2mediated fatty acid transport. Each of these compounds has proven to be functional in
specifically blocking fatty acid transport without affecting the downstream fatty acid
activation. These five compounds are different from the FATP4-specific inhibitors identified
by Blackburn, et al. using a similar high throughput approach [27]. Those compounds, 4aryl-3,4-dihydropyrimidin-2(1H)-ones, were structurally distinct from the compounds we have
identified. Identification of compounds with unique structural characteristics was not
surprising since different FATP orthologues were used in the primary selection by Blackburn
and coworkers compared with the screens reported herein.
In conclusion, this study identified and characterized five diverse compounds that inhibit
FATP-mediated fatty acid transport in the low micromolar range. Each compound specifically
blocks fatty acid transport without impacting other cellular functions and thus is tractable as
tools to determine the underlying mechanistic features of the fatty acid transport protein family.
An important outcome is that these compounds or structurally related derivatives may provide
eventual therapeutic use for disease states in which lipotoxicity is a primary or confounding
factor.
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Abbreviations
Acsl

acyl-CoA synthetase long chain

FAF BSA

fatty acid free bovine serum albumin

FATP

fatty acid transport protein

C1-BODIPY-C12

4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic

HTS

high throughput screening
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MEM

minimal essential media

MTT

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

2-NBDG

2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose

TEER

transepithelial electrical resistance
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Fig. 1.

Titration of selected compounds yields sigmoidal dose-response curves for the inhibition of
C1-BODIPY-C12 uptake into Caco-2 cells. Curves were fit using dose-response nonlinear
least-squares regression models in Prism software. (A) compound CB-2; (B) compound CB-5;
(C) compound CB-6; (D) compound CB-16; and (E) compound NCI-3. Values are presented
as means ± SE for 3–4 experiments assayed in triplicate.
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Fig. 2.
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Dose-response curves for the inhibition of C1-BODIPY-C12 uptake into 3T3-L1 adipocytes.
Curves were fit using dose-response nonlinear least-squares regression models in Prism
software. (A) compound CB-2; (B) compound CB-5; (C) compound CB-6; (D) compound
CB-16.1; and (E) compound NCI-3. Values are presented as means ± SE for 4 experiments
assayed in triplicate.
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Fig. 3.

The selected compounds are not toxic to cells. Caco-2 cells were treated with CB-2, CB-5,
CB-6 or CB-16 at 50 μM, or NCI-3 at 100 μM for 24 h then the MTT assay was performed to
assess mitochondrial function, an indicator of cellular toxicity. Bar height indicates the mean
value ± standard deviation for 2 experiments assayed in triplicate.
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Fig. 4.
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Evaluation of barrier and membrane function of Caco-2 cells after compound treatment. (A)
Trans-epithelial electrical resistance (TEER) was measured in fully differentiated Caco-2 cells
after one hour treatment with two different concentrations of selected compounds as shown.
Caco-2 cells were seeded and differentiated in Collagen-Coated Transwell®-COL Inserts.
TEER was measured using a Millipore Millicell®-ERS device. (B) Transport of the glucose
analogue 2-NBDG was measured in Caco-2 cells seeded and differentiated in 96-well plates.
Final concentrations of compounds were 20 μM for compounds CB-2, CB-5, CB-6 and CB-16;
and 50 μM for compound NCI-3. Bar height indicates mean values ± standard deviation for
3–5 independent experiments assayed in duplicate (A) and triplicate (B) respectively.
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Fig. 5.

Inhibition of uptake of [3H]C18:1 into Caco-2 cells. Caco-2 cells were preincubated for one
hour with selected compounds (final concentrations were 20 μM for compounds CB-2, CB-5,
CB-6 and CB-16; and 50 μM for compound NCI-3) followed by the addition of [3H]C18:1 for
3 minutes as detailed in the text. Bar height indicates the mean values ± standard deviation for
3–5 independent experiments.
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Fig. 6.

Assessment of oleoyl (C18:1)-CoA synthetase activity after compound treatment. Cells were
treated for 1 h at the indicated final concentration, then cell extracts were prepared and Acsl
activity measured. Bar height indicates mean values ± standard deviation for 3–5 independent
experiments assayed in duplicate.
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5584680

Compound ID
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5674122

Chemical Structure a
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nd activity of inhibitory compounds

4.93 ± 0.40

6.72 ±0.81

10.15 ± 1.26

7.55 ± 1.23

3.99 ± 0.32

6.34 ± 0.93

HepG2 IC50 (μM)

Caco-2 IC50 (μM)b

231.1 ± 33.5

3T3-L1
Adipocytes
IC50 (μM)

52.5 ± 6.7

900.9 ± 204.6
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Compound ID
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Code

HepG2 IC50 (μM)
ND

Caco-2 IC50 (μM)b
6.66 ± 0.64
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Chemical Structure a
ND

3T3-L1
Adipocytes
IC50 (μM)
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HepG2 IC50 (μM)
84.12 ± 14.12

29.22 ± 3.64

e averages of 3 experiments plus and minus the standard error of the mean. ND, not determined

ames: CB2, (5E)-5-[(3-bromo-4-hydroxy-5-methoxyphenyl)methylene]-3-(3-chlorophenyl)-2-thioxothiazolidin-4-one; CB5, 2-benzyl-3-(4-chlorophenyl)-5-(4-nitrophenyl)-1H-pyrazolo[5,1-b]
e; CB6, 2-[7-(trifluoromethyl)-2,3-dihydro-1H-1,4-diazepin-5-yl]naphthalen-1-ol; CB16, 5′-bromo-5-(6-oxocyclohexa-2,4-dien-1-ylidene)spiro[1,3,4-thiadiazolidine-2,3′-1H-indole]-2′-one;
bis(1H-indol-3-yl)butan-1-ol
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Caco-2 IC50 (μM)b
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Chemical Structure a

142.9 ± 22.4

3T3-L1
Adipocytes
IC50 (μM)
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TABLE 2

Compound inhibition is reversible
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Compounda
Control (no compound)

% Transport Standard Assayb

% Transport after 24 Hour Recovery

100

100

CB-2

46 ± 3

93 ±13

CB-5

54 ± 1

88 ±18

CB-6

35 ± 1

74 ± 12

CB-16

27 ± 1

99 ± 16

NCI 3

52 ± 2

99 ±16

a

All compounds added at f.c. 40 μM to Caco-2 cells

b

Numbers are the mean of 3–5 experiments ± the standard deviation
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TABLE 3

Analysis of compounds structurally related to CB-2, CB-5, CB-6 and CB-16 in Caco-2 cells
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CB-2

R2
S
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A. CB-2
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A. CB-2
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Compound

R1

R2

CB-2.2

S

CB-2.3

S

CB-2.4

O
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A. CB-2
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R1

CB-2.5

R2
O
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B. CB-5

Compound

R1

R2

IC50 (μM)

CB-5

NO2

Cl

6.34 ± 0.93
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B. CB-5
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Compound

R1

R2

IC50 (μM)

CB-5.1

NO2

OCH3

17.3 ± 3.01

CB-5.2

NO2

H

16.4 ± 2.22

CB-5.3

H

CL

76.9 ± 15.7

C. CB-6
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IC50
4.93
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C. CB-6
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CB-6.1

IC50

241
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Compound

R1

R2

IC50 (μM)

CB-16

OH

Br

6.66 ± 0.64

CB-16.1

OH

H

11.9 ± 1.43

CB-16.2

H

Br

4.84 ± 0.69
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